This product is a RPMI 8226 B cell engineering tool based on the Gold nanoparticles (Hyaluronic acid/ RHAMM, CD44) delivery system and CRISPR-based (AAVS1-tracr RNA-Cas9-(Z)-4-Hydroxytamoxifen ) genome editor.
| Host Cell | RPMI 8226 |
| Target | CD47 |
| Insert Clone | 3F3-xi |
| Safe Harbor Sites (SHS) | AAVS1 |
| gRNA | tracr RNA |
| Nuclease | Cas9 |
| Enhancer | (Z)-4-Hydroxytamoxifen |
| Targeting Strategy | pH responsive |
| Insertion sites | Large DNA sequences |
| Vehicles | Gold nanoparticles |
| Ligand/Receptor | Hyaluronic acid/ RHAMM, CD44 |
| Active Agents | AntimiR-21, doxorubicin (DOX) |
| Particle Size | <500 |
| Charge (mv) | ≤50 |
| Total Atom Count | ~65,000,000 |
| Surface Atoms (%) | ~0.6 |
| Specific Surface Area (m2/g) | ~0.8 |
| Vector Type | Lentivirus |
| Vector Name | BCpCDH2 |
| Targeting Diseases | Ovarian cancer; Breast cancer; Colon cancer |
Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.